CAR-T cell therapy for solid tumors: antigen landscape, biological barriers, and engineering strategies for clinical translation
Chimeric Antigen Receptor T (CAR-T) cell therapy has emerged as a promising therapeutic option, particularly for refractory and relapsed leukemias. However, its efficacy in treating solid tumors, including lung, ovarian, gastric, and breast cancers, re…